FOLH1 and neoplasm: This is likely due to limited expression of GCP-II at tumor sites, as depicted with 18F-DCFPyL PET/CT, along with the high background activity in the liver and spleen and in segments of the gastrointestinal tract, limiting detection of subdiaphragmatic or capsular hepatic metastases and serosal deposits (Figures 3A–G).